Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dual inhibition of FACT and RRM2 suppresses the progression of pancreatic ductal adenocarcinoma driven by the oncohistone H2BG53D.

Cell reports - 23 Dec 2025

Qin Tiantian, Wan Yi Ching Esther, Hu Shiman, Chen Jiaohua, Zhu Xiaoxuan, Zhou Jiaqi, Chen Yabin, Wang Xin, Zheng Zongli, Chan Landon Long, Wong Hoi Leong Xavier, Jin Haojie, Han Junhong, Li Qing, Gan Haiyun, Chan Kui Ming

Abstract excerpt

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with frequent genetic mutations. We previously reported the identification of the histone H2BG53D mutation and revealed that this mutation destabilizes nucleosomes and promotes cell migration. However, how H2BG53D impacts chromatin and its significance in PDAC development remain unknown. Using genetically engineered mouse models, we demonstrate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Pancreatic Ductal
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Progression

Share to DNA-Binding Proteins

Share to Histones

Share to Nucleosomes

Share to Pancreatic Neoplasms

Share to Ribonucleoside Diphosphate Reductase

Source

Identifiers

PMID: 41284383
DOI: 10.1016/j.celrep.2025.116596

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dual inhibition of FACT and RRM2 suppresses the progression of pancreatic ductal adenocarcinoma driven by the oncohistone H2BG53D.PMID 41284383Read ↗

Loss of Setd2 promotes Kras-induced acinar-to-ductal metaplasia and epithelia–mesenchymal transition during pancreatic carcinogenesisSemantic proximity Read ↗

The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programsSemantic proximity Read ↗

SETting the Stage for Cancer Development: SETD2 and the Consequences of Lost Methylation.Semantic proximity Read ↗

Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethalitySemantic proximity Read ↗

Loss of Chromatin-Remodeling Proteins and/or CDKN2A Associates With Metastasis of Pancreatic Neuroendocrine Tumors and Reduced Patient Survival Times.Semantic proximity Read ↗

The interaction between UBR7 and PRMT5 drives PDAC resistance to gemcitabine by regulating glycolysis and immune microenvironmentSemantic proximity Read ↗

HNF1A recruits UTX to activate a differentiation program that suppresses pancreatic cancerSemantic proximity Read ↗

SETD2 as a regulator of N6-methyladenosine RNA methylation and modifiers in cancer.Semantic proximity Read ↗

Marker-based CRISPR screening reveals a MED12-p63 interaction that activates basal identity in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Loss of the H4 lysine methyltransferase KMT5B drives tumorigenic phenotypes by depleting H3K27me3 at loci otherwise retained in H3K27M mutant DIPG cellsSemantic proximity Read ↗

Inhibiting NR5A2 targets stemness in pancreatic cancer by disrupting SOX2/MYC signaling and restoring chemosensitivitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.